Treatment of Sarcoidosis-Associated Pulmonary Hypertension.

The article presents the results of a study on the experience of two health care centers in New York in the management of patients with sarcoidosis-associated pulmonary arterial hypertension (PAH). According to the authors, 22 patients with sarcoidosis treated with PAH-specific therapies experienced an increase in their mean six-minute walk distance, a greater increment in exercise capacity, and reduce in mean pulmonary artery pressure. They add that the survival rates of one- and three-year transplant free patients ranged from 74 to 90 percent.